Objective. *Candida* species colonize the vagina in at least 20% of women, with rates rising to 30% during pregnancy. This study aimed at determining the prevalence and risk factors of vulvovaginal candidiasis (VVC) in pregnant women at 35–37 weeks of gestation. It also aims at finding possible correlations between VVC and vaginal colonization by other agents, such as *Group B Streptococcus* (GBS) and bacterial vaginosis. 

**Methodology.** Over a one-year period, high vaginal swabs were collected from pregnant women during their regular antenatal checkup in different polyclinics in Beirut and South Lebanon. Swabs were examined microscopically, cultured on Sabouraud Dextrose Agar, and *Candida* isolates were identified using Chromatic *Candida* medium and Germ Tube Test.

**Results.** VVC was detected in 44.8% of samples, with *C. glabrata* (44.4%) and *C. albicans* (43.4%) being the most isolated species. Approximately, half of pregnant women (57.7%) were coinfected with *Candida* and bacterial vaginosis, while 26% of them carried simultaneously *Candida* spp. and GBS. No significant correlation was found between the occurrence of VVC and demographic, clinical, medical, and reproductive health characteristics of pregnant women. In contrast, participants with previous miscarriages and those being hospitalized during the past 12 months were more susceptible to develop vaginal *C. krusei* infection in comparison to other *Candida* species (p=0.0316 and p=0.0042, respectively).

**Conclusion.** The prevalence of VVC in pregnant women is an increasing trend in our community. Therefore, routine medical examination and regular screening for candidiasis in the antenatal care program is highly recommended to manage the disease and its complications.

1. **Introduction**

Vulvovaginal candidiasis (VVC) is an opportunistic mucosal infection and the second most common vaginal infection affecting women of reproductive age [1]. It affects more than 75% of women at least once in their lifetime, with approximately 50% of them also suffering a single recurrence [1, 2]. The clinical symptoms and manifestations of VVC include cottage cheese-like vaginal discharge, swelling, pruritus, pain, irritation, burning sensation, dyspareunia, and dysuria [1, 3].

Several studies have shown that prevalence of *Candida* among pregnant women is higher than that in nonpregnant women, and it tends to increase with the progression of the pregnancy [4–7]. Some emerging data have also suggested that VVC during pregnancy might be associated with increased risk of complications, such as premature rupture of membranes, preterm labor, chorioamnionitis, and congenital cutaneous candidiasis [8].

Different factors related to physiologic changes, such as decreased cellular immunity, elevated hormone levels, reduced vaginal pH, and increased vaginal glycogen concentration, have been associated with a higher risk of VVC during pregnancy [6, 9, 10]. *Candida* colonization is also considered to be a consequence of broad-spectrum antibiotic use and has been reportedly associated with a decreased colonization of *Lactobacillus*, probably resulting from the interference with epithelial binding sites [5]. Indeed, when balance between *Candida*, normal bacterial flora, and immune defense mechanisms is disturbed, colonization is replaced by infection.
According to most reports, *C. albicans* is responsible for the largest number of VVC, contributing to 85-90% of symptomatic episodes of vaginal candidiasis [5]. Non-*albicans* *Candida* species, including among others *C. glabrata*, *C. tropicalis*, and *C. krusei*, are now emerging as identifiable causes of VVC and differ considerably with regard to epidemiology, virulence, and antifungal drug susceptibility [2, 3, 11].

Invasive candidiasis in neonates is becoming a serious and common cause of late onset sepsis, with mortality rates reaching as high as 25-35% [12]. The incidence of such fungal infections has increased 11-fold over the past 15 years, and *Candida* species are currently considered as the third most frequent organism isolated in late onset sepsis in very low birth weight infants [12].

In this regard, the present study was conducted to determine the prevalence of VVC and other vaginal colonization among Lebanese pregnant women, as well as the frequency of distribution of *C. albicans* and non-*albicans* *Candida* species in vaginal cultures. It also aims to assess the demographic and clinical profiles of pregnant women and to determine risk factors contributing to the emergence of the disease during pregnancy.

### 2. Materials and Methods

#### 2.1. Study Design and Samples Collection

The study was conducted according to the Declaration of Helsinki and approved by the Ethical Committee of Notre Dame University Hospital. A total of 221 pregnant women, in their 35-37 weeks of gestation, presenting at the outpatient clinic of obstetrics and gynecology department of different hospitals and peripheral clinics in Lebanon, were enrolled in this study between September 2016 and August 2017. After obtaining a written and verbal informed consent from all participants, vaginal swabs were collected by the gynecologist from pregnant women during their regular antenatal care checkup using a one cotton-tipped swab with Stuart media (Oxoid, United Kingdom). Samples were then submitted from pregnant women during their regular antenatal care checkup using a one cotton-tipped swab with Stuart media (Oxoid, United Kingdom). Samples were then submitted to culture, and a questionnaire was filled by the attending physician for the first 107 participants enrolled in the study to gather relevant information regarding socio-demographic data, clinical symptoms, personal medical history, treatment, and risk factors for vaginal colonization.

#### 2.2. Isolation and Identification of Candida Species

Vaginal swabs were inoculated on Sabouraud Dextrose Agar (SDA) (Liofilchem, Italy) for fungi isolation and incubated at 37 °C for 48h. Direct wet mount examination and Gram staining were performed for all suspected colonies, and isolates were recultured on SDA for 48h at 35 °C for purity purposes. Positive *Candida* cultures were further identified to the species level by the Chromatic *Candida* medium (Liofilchem, Italy) that allows the selective isolation and differentiation of *Candida* spp. based on colony color and morphology. The chromatic agar has been well documented in previous studies as for its high sensitivity and specificity for the identification of the most commonly encountered *Candida* spp. [13–15]. After 72h of incubation of Chromatic *Candida* plates at 37 °C, green colonies were identified as *C. albicans*, creamy colored colonies were regarded as *C. glabrata*, and *C. krusei* colonies were pink with a whitish border. *C. albicans* isolates were further confirmed by germ tube test.

#### 2.3. Isolation and Identification of Bacterial Colonization and Bacterial Vaginosis

Swabs were cultured in various solid selective media, namely 5% blood agar for the isolation of Group B Streptococci (GBS), and Mannitol Salt agar (Liofilchem, Italy) for *Staphylococcus aureus* isolation. After 24h incubation at 37 °C, colonies were identified routinely by morphological and biochemical tests. Bacterial vaginosis identification was based on the obstetrician clinical assessment or on the detection of clue cells in the direct Gram staining.

#### 2.4. Statistical Analysis

Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA, USA). Means and standard deviations for quantitative variables were calculated. The search for factors associated with vaginal candidiasis was performed by Chi square exact test comparing frequencies between groups. Fisher’s exact test was used where appropriate. P values less than 0.05 were considered significant.

### 3. Results

#### 3.1. Demographic and Clinical Characteristics of Participants

Based on the questionnaire filled by 107 pregnant women, the participants’ age ranged from 20 to 40 years. The majority of studied women (71.9%) had a tertiary education level, while only 8.4% of them were illiterate. A symptomatic VVC was detected in 82% of pregnant women, with the most frequently reported symptoms including abnormal vaginal discharge (67%), itching (22%), and malodor (11%).

#### 3.2. Prevalence of VVC and Bacterial Vaginal Colonization

Out of the 221 high vaginal swabs collected during the study period, 99 (44.8%) were found to be positive for *Candida*. The prevalence of *C. albicans* infections was 43.4%, while non-*albicans* *Candida* strains counted for 56.6% of VVC, the main identified species being *C. glabrata* (44.5%) followed by *C. krusei* observed only in 12.1% of vaginal candidiasis. In 2% of cases, women were infected with *C. albicans* and *C. glabrata* concurrently.

On the other hand, rates of bacterial colonization were, respectively, 11.7% (n=26) for bacterial vaginosis, identified by the presence of vaginal discharge and clue cells visualized under microscope, 20.8% (n=46) for GBS and 5% (n=11) for *Staphylococcus aureus*. The most prevalent coinfection with *Candida* was bacterial vaginosis as 57.7% of pregnant women with bacterial vaginosis carried simultaneously different *Candida* species. However, only 26% of colonized women were coinfected with GBS and *Candida*.

#### 3.3. Correlation of Demographic and Clinical Characteristics of Participants with the Occurrence of VVC

The isolation rates of VVC with regard to age, level of education, and type
of symptoms are shown in Table 1. Women aged between 26 and 30 years and those with primary education level had the highest frequencies of *Candida*-positive cultures, but without any significant association between all these factors and the occurrence of VVC \((p = 0.4789\) and \(p=0.2266,\) respectively) (Table 1). Moreover, no significant correlation was found between the isolation frequencies of *Candida* species and the presence of clinical symptoms, namely vaginal discharge, itching, and malodor \((p=0.5303, p=0.1826,\) and \(p=0.3697,\) respectively) (Table 1).

### 3.4. Correlation of Demographic and Clinical Characteristics of Participants with Candida Species Distribution

Statistical analyses of demographic data of patients showed no significant difference in *Candida* species distribution with regard to age \((p=0.7755)\) and level of education \((p=0.1994)\) (Table 2). Moreover, correlation of vulvovaginal symptoms with *Candida* species distribution showed that vaginal discharge was more frequent in *C. albicans* (44.4%) rather than non-*albicans* vaginal candidiasis. As for itching, it was exclusively found in *C. albicans* infections, while malodor rates were comparable regardless of the species isolated (Table 2). While vaginal discharge and malodor seem not to be related to *Candida* species distribution \((p=0.4293\) and \(p=0.6276,\) respectively), the presence of itching in pregnant women was found to be significantly associated with a higher occurrence of *C. albicans* infections \((p=0.0317)\) (Table 2).

### 3.5. Correlation of Medical and Reproductive Health Characteristics of Participants with VVC Prevalence and Candida Species Distribution

The prevalence of VVC and the distribution of *Candida* species were also assessed in relation to patient’s medical history, as well as to previous and current treatment and reproductive health characteristics. As shown in Table 3, there was no significant difference in the frequencies of *Candida* infection with regard to all variables investigated in the present study, thus suggesting that none of these variables can be considered as a risk factor for vaginal candidiasis in Lebanese pregnant women.

Interestingly, women with previous miscarriages and those being hospitalized during the past 12 months showed a significant differential distribution in *Candida* species, with an increased susceptibility to develop vaginal *C. krusei* infection in comparison to other *Candida* species \((p=0.0316\) and \(p=0.0042,\) respectively) (Table 4).

### 4. Discussion

VVC represents one of the most frequent infections of the genital tract affecting millions of women each year [2]. Several studies evaluating the prevalence of candidiasis among pregnant women showed that the distribution of isolated *Candida* species varies between countries, and it is greatly depending on several risk factors such as age, hygienic habits, and disease history [2, 6, 10, 16]. To the best of our knowledge, this is the first study investigating the prevalence of vaginal candidiasis among pregnant women in Lebanon. Our results showed a rate of 44.8% of VVC among the studied population which is clearly higher than that observed by Ramia *et al.* in 2012 on a sample of 441 Lebanese nonpregnant women [17], thus highlighting the higher occurrence of VVC during pregnancy. Data obtained were on the other hand comparable to frequencies reported by studies conducted in Libya, Tanzania, Kenya, and Turkey (43.8%, 42.9%, 42.7%, and 37.4%, respectively) [6, 18, 19], but higher than that observed in Kuwait (13%) [2].

The high rate of infection observed in this study can be attributed to the fact that *Candida* infections tend to increase throughout pregnancy due to high levels of placental estrogens, progesterone, and corticosteroids that can reduce the vaginal defense mechanisms and facilitate the growth of yeasts [20, 21]. Moreover, pregnant women are usually more prone to infections because of the weakened immune system and the prolonged misuse of antibiotics during pregnancy [19, 22, 23].

As reported by previous studies, the majority of participants (94%) harbored only one *Candida* species, whereas only 6% of pregnant women were coinfected with more than two yeast isolates [2, 3, 24]. *C. glabrata* was the most frequently isolated species (44.5%) followed by *C. albicans* (43.4%) and *C. krusei* (12.1%). The higher percentage of occurrence of VVC attributed to non-*albicans* *Candida* species (56.6%) compared to that related to *C. albicans* species is

---

**Table 1: Frequency of *Candida* infections with regard to socio-demographic and clinical characteristics of patients.**

| Variables         | Negative N (%) | Positive N (%) | P value |
|-------------------|----------------|----------------|---------|
| **Age group**     |                |                |         |
| 20 - 25           | 7 (87.5)       | 1 (12.5)       |         |
| 26 - 30           | 27 (65.9)      | 14 (34.1)      | 0.4789  |
| 31 - 40           | 40 (69)        | 18 (31)        |         |
| **Level of education** |            |                |         |
| None              | 6 (66.6)       | 3 (33.3)       |         |
| Primary           | 5 (62.5)       | 3 (37.5)       | 0.2266  |
| Secondary         | 9 (69.9)       | 4 (30.7)       |         |
| Tertiary          | 54 (70.2)      | 23 (29.8)      |         |
| **Clinical symptoms** |              |                |         |
| Discharge         |                |                |         |
| Yes               | 34 (65.4)      | 18 (34.6)      | 0.5303  |
| No                | 40 (72.8)      | 15 (27.2)      |         |
| Itching           |                |                |         |
| Yes               | 6 (50)         | 6 (50)         | 0.1826  |
| No                | 68 (71.6)      | 27 (28.4)      |         |
| Malodor           |                |                |         |
| Yes               | 3 (50)         | 3 (50)         | 0.3697  |
| No                | 71 (70.3)      | 30 (29.7)      |         |

N: number of individuals; Chi square test was performed to generate p values for differences in *Candida* infection frequencies with regard to age, level of education, and clinical symptoms. Fisher’s exact test was used where appropriate.
Table 2: *Candida* spp. distribution with regard to patients’ demographic and clinical symptoms.

| Variables          | *C. albicans* N (%) | *C. glabrata* N (%) | *C. krusei* N (%) | P value |
|--------------------|---------------------|---------------------|-------------------|---------|
| Age group          |                     |                     |                   |         |
| 20 - 25            | 1 (100)             | 0 (0)               | 0 (0)             | 0.7755  |
| 26 – 30            | 6 (42.8)            | 5 (35.7)            | 3 (21.5)          |         |
| 31 - 40            | 10 (55.5)           | 6 (33.3)            | 2 (11.2)          |         |
| Level of education |                     |                     |                   |         |
| None               | 2 (66.7)            | 1 (33.3)            | 0 (0)             |         |
| Primary            | 0 (0)               | 1 (33.3)            | 2 (66.7)          | 0.1994  |
| Secondary          | 2 (50)              | 2 (50)              | 0 (0)             |         |
| Tertiary           | 13 (56.5)           | 7 (30.4)            | 3 (13.1)          |         |
| Clinical Symptoms  |                     |                     |                   |         |
| Discharge          |                     |                     |                   |         |
| Yes                | 8 (44.5)            | 6 (33.3)            | 4 (22.2)          |         |
| No                 | 9 (60)              | 5 (33.3)            | 1 (6.7)           | 0.4293  |
| Itching            |                     |                     |                   |         |
| Yes                | 6 (100)             | 0 (0)               | 0 (0)             |         |
| No                 | 11 (40.7)           | 11 (40.7)           | 5 (18.6)          | 0.0317  |
| Malodor            |                     |                     |                   |         |
| Yes                | 1 (33.3)            | 1 (33.3)            | 1 (33.3)          |         |
| No                 | 16 (53.3)           | 10 (33.3)           | 4 (13.4)          | 0.6276  |

N: number of individuals; Chi square test was performed to generate p values for differences in *Candida* species distribution with regard to age, level of education, and clinical symptoms.

consistent with data reported in recent studies [25]. Indeed, a remarkable increase in the incidence of isolation rate of non-*albicans Candida* species has been recently observed in several Asian and African countries, with *C. glabrata* regarded as the most common associated species with VVC [2, 3, 16, 20, 24–26]. These non-*albicans Candida* species are comparatively nonpathogenic, but eventually they are elected, and begin emerging frequently due to the extensive misuse of over the counter antifungals, the use of single-dose oral and topical azoles treatments, and the long-standing protection treatments of oral azoles [25].

The distribution of *Candida* infection frequencies with regard to age and level of education showed that women aged between 26 and 30 years and those with primary education had the highest rates of infection (Table 1). These results may be related to the high sexual activity of participants belonging to this group as well as to the fact that these women are more likely to indiscriminate drug and contraceptives usage to prevent pregnancy [18]. In agreement with findings from other groups [11, 18, 27], *C. albicans* was the predominant isolate from women of childbearing age (Table 2). Indeed, the high levels of estrogen in the latter group induce the formation and deposition of glycogen in the vagina, thus providing a favorable environment for the growth of *C. albicans* [28]. As for results regarding the level of education, they may be related to the lack of knowledge of women with primary education in preventing and reducing risk of candidiasis.

The most common symptoms observed in Lebanese pregnant women with VVC were in accordance with findings in the literature and included mainly vaginal discharge, itching, and malodor that can interfere with the normal daily life of women [1]. Analysis of the distribution of these symptoms among different *Candida* species revealed that vaginal discharge and itching are more frequent in *C. albicans* in comparison to other *Candida* species, as it would be presumably due to its virulence [9].

The increased risk for VVC during pregnancy may be related to several factors, such as sociodemographic and clinical profile of patients, as well as personal medical history, reproductive health characteristics, and previous and current treatment. In this regard, we investigated the possibility of an association between all these factors and susceptibility to VVC. As shown in Tables 1 and 3, none of the factors investigated was significantly associated with the occurrence of VVC, thus suggesting that all of them cannot be considered as major determinants for *Candida* infection in Lebanon. Previous reports have revealed that multigravida women more often suffer from VVC due to longer sexual histories and more pregnancies, hence making them more prone to developing VVC [6]. However, in the present study the number of children did not correlate with the occurrence of *Candida* infection, which may be related to the limited sampling number. Findings related to patient’s medical history and use of antibiotics were similar to some reports [4, 29, 30] but contradictory to others [9, 22, 31] and
Table 3: Frequency of *Candida* infections with regard to reproductive health characteristics, patient's medical history, and previous and current treatment.

| Variables                  | Negative N (%) | Positive N (%) | P value |
|----------------------------|----------------|----------------|---------|
|                            | N (%)          | N (%)          |         |
| **Previous Miscarriage**   |                |                |         |
| Yes                        | 22 (68.8)      | 10 (31.2)      | 1       |
| No                         | 52 (69.4)      | 23 (30.6)      |         |
| **Number of Children**     |                |                |         |
| 0                          | 40 (71.5)      | 16 (28.5)      | 0.8677  |
| 1                          | 26 (66.7)      | 13 (33.3)      |         |
| ≥ 2                        | 8 (66.7)       | 4 (33.3)       |         |
| **Clinical History**       |                |                |         |
| None                       | 37 (74)        | 13 (26)        | 0.2435  |
| Diabetes                   | 13 (50)        | 13 (50)        |         |
| Gestational Diabetes       | 4 (57.2)       | 3 (42.8)       | 0.02435 |
| Anemia                     | 12 (57.2)      | 9 (42.8)       |         |
| Urinary Tract Infection    | 0 (0)          | 1 (100)        |         |
| Recurrent vaginitis        | 1 (50)         | 1 (50)         |         |
| **Vaginitis**              |                |                |         |
| Yes                        | 12 (57.2)      | 9 (42.8)       | 0.1970  |
| No                         | 62 (71.3)      | 24 (27.9)      |         |
| **Vaginosis**              |                |                |         |
| Yes                        | 8 (72.8)       | 3 (27.2)       | 1       |
| No                         | 66 (68.8)      | 30 (31.2)      |         |
| **Treatment**              |                |                |         |
| **Antibiotic**             |                |                |         |
| Yes                        | 2 (33.3)       | 4 (66.7)       | 0.0715  |
| No                         | 72 (71.3)      | 29 (28.7)      |         |
| **Antiseptic**             |                |                |         |
| Yes                        | 46 (69.7)      | 20 (30.3)      | 1       |
| No                         | 28 (68.3)      | 13 (31.7)      |         |
| **Antifungal**             |                |                |         |
| Yes                        | 4 (57.2)       | 3 (42.8)       | 0.6738  |
| No                         | 70 (70)        | 30 (30)        |         |
| **Previous GBS isolation**|                |                |         |
| Yes                        | 4 (80)         | 1 (20)         | 0.6646  |
| No                         | 70 (68.7)      | 32 (31.3)      |         |
| **Antibiotic over last 12 months** |            |                |         |
| Yes                        | 12 (63.2)      | 7 (36.8)       | 0.5877  |
| No                         | 62 (70.5)      | 26 (29.5)      |         |
| **Hospitalization last 12 months** |            |                |         |
| Yes                        | 6 (54.5)       | 5 (45.5)       | 0.3086  |
| No                         | 68 (70.9)      | 28 (29.1)      |         |

N: number of individuals; Chi square test was performed to generate p values for differences in *Candida* infection frequencies with regard to reproductive health characteristics, patient's medical history, and previous and current treatment; Fisher's exact test was used where appropriate.

may be attributed to differences in study designs, as well as geographic determinants, dietary and hygiene habits, and sociocultural traits of participants.

Interestingly, our results showed a significant association between the presence of previous miscarriages and hospitalization with *Candida* species distribution. Women with previous miscarriages and those being hospitalized during the past 12 months were more likely to develop *C. krusei* infection in comparison to other *Candida* species (p=0.0316 and p=0.0042; Table 3). *C. krusei* has been described as a
Table 4: *Candida* spp. distribution with regard to reproductive health characteristics, patient’s medical history, and previous and current treatment.

| Variables                        | *C. albicans* N (%) | *C. glabrata* N (%) | *C. krusei* N (%) | P value |
|----------------------------------|---------------------|--------------------|-------------------|---------|
| **Previous Miscarriage**         |                     |                    |                   |         |
| Yes                              | 4 (40)              | 2 (20)             | 4 (40)            | 0.0316  |
| No                               | 14 (60.8)           | 8 (34.8)           | 1 (4.4)           |         |
| **Number of Children**           |                     |                    |                   |         |
| 0                                | 8 (50)              | 7 (43.8)           | 1 (6.2)           | 0.3556  |
| 1                                | 7 (53.8)            | 3 (23.1)           | 3 (23.1)          |         |
| ≥ 2                              | 3 (75)              | 0 (0)              | 1 (25)            |         |
| **Medical History**              |                     |                    |                   |         |
| None                             | 9 (69.2)            | 3 (23.1)           | 1 (7.7)           |         |
| Diabetes                         | 6 (46.1)            | 4 (30.7)           | 3 (23.2)          | 0.6644  |
| Gestational Diabetes             | 3 (100)             | 0 (0)              | 0 (0)             |         |
| Anemia                           | 3 (33.3)            | 4 (44.5)           | 2 (22.2)          |         |
| Urinary Tract Infection          | 1 (100)             | 0 (0)              | 0 (0)             |         |
| Recurrent vaginitis              | 1 (100)             | 0 (0)              | 0 (0)             |         |
| **Vaginitis**                    |                     |                    |                   |         |
| Yes                              | 5 (55.6)            | 2 (22.2)           | 2 (22.2)          | 0.7127  |
| No                               | 13 (54.1)           | 8 (33.3)           | 3 (12.6)          |         |
| **Vaginosis**                    |                     |                    |                   |         |
| Yes                              | 2 (66.7)            | 1 (33.3)           | 0 (0)             | 0.7412  |
| No                               | 16 (53.3)           | 9 (30)             | 5 (16.7)          |         |
| **Treatment**                    |                     |                    |                   |         |
| **Antibiotic**                   |                     |                    |                   |         |
| Yes                              | 3 (75)              | 1 (25)             | 0 (0)             | 0.5295  |
| No                               | 14 (48.2)           | 10 (34.4)          | 5 (17.4)          |         |
| **Antiseptic**                   |                     |                    |                   |         |
| Yes                              | 11 (55)             | 5 (25)             | 4 (20)            | 0.3744  |
| No                               | 6 (46.1)            | 6 (46.1)           | 1 (7.8)           |         |
| **Antifungal**                   |                     |                    |                   |         |
| Yes                              | 3 (100)             | 0 (0)              | 0 (0)             | 0.2116  |
| No                               | 14 (46.6)           | 11 (36.6)          | 5 (16.8)          |         |
| **Previous GBS isolation**       |                     |                    |                   |         |
| Yes                              | 1 (100)             | 0 (0)              | 0 (0)             | 0.6115  |
| No                               | 16 (50)             | 11 (36.3)          | 5 (15.7)          |         |
| **Antibiotic over last 12 months**|                     |                    |                   |         |
| Yes                              | 4 (57.1)            | 3 (42.9)           | 0 (0)             | 0.4399  |
| No                               | 13 (50)             | 8 (30.7)           | 5 (19.3)          |         |
| **Hospitalization last 12 months**|                     |                    |                   |         |
| Yes                              | 0 (0)               | 2 (40)             | 3 (60)            | 0.0042  |
| No                               | 17 (60.7)           | 9 (32.1)           | 2 (7.2)           |         |

N: number of individuals; Chi square test was performed to generate p values for differences in *Candida* species distribution with regard to reproductive health characteristics, patient’s medical history, and previous and current treatment.

Causative agent of disseminated fungal infections in susceptible patients and has been associated with a statistically significant increased risk of spontaneous abortion in pregnant women treated with antifungals [32].

5. Conclusion

The high frequency of *Candida* recovered among Lebanese pregnant women represents a major public health concern.
Additional studies on a larger sample and evaluating other potential factors related to VVC are of great importance to prevent and reduce risk of Candida infections among Lebanese pregnant women. Moreover, the role of non-albicans Candida in recurrent VVC warrants further investigation, due to the increased frequency of resistant non-albicans Candida species isolated from vaginal samples. Routine medical examination, adequate antenatal services, and regular screening for candidiasis with antifungal susceptibility testing are highly recommended for a better monitoring of the disease and its burden among Lebanese pregnant women.

Data Availability
The data in the tables used to support the findings of this study are included within the article.

Disclosure
Nahed Ghaddar and Ali El Roz, both coauthors, equally contributed to this study.

Conflicts of Interest
The authors declare that they have no conflict of interest.

Acknowledgments
The authors thank the Lebanese German University and Dr. Mohammad Lakkis for their support.

References
[1] T. J. Aguin and J. D. Sobel, "Vulvovaginal candidiasis in pregnancy," Current Infectious Disease Reports, vol. 17, no. 6, article 462, 2015.
[2] W. Alfozun, R. Dhar, H. Ashkanani, M. Gupta, C. Rachel, and Z. Khan, "Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait," Journal de Mycologie Médicale, vol. 25, no. 1, pp. 23–28, 2015.
[3] S. R. Fan, X. P. Liu, and J. W. Li, "Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006," Journal of Obstetrics and Gynecology Research, vol. 34, no. 4, pp. 561–566, 2008.
[4] M. F. Cotch, S. L. Hillier, R. S. Gibbs, D. A. Eschenbach, and Vaginal Infections and Prematurity Study Group, "Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy," American Journal of Obstetrics & Gynecology, vol. 178, no. 2, pp. 374–380, 1998.
[5] M. Babić and M. Hukić, "Candida albicans and non-albicans species as etiological agent of vaginitis in pregnant and non-pregnant women," Bosnian Journal of Basic Medical Sciences, vol. 10, no. 1, pp. 89–97, 2010.
[6] A. B. Guzel, M. Ilkık, R. Burgut, I. F. Urusnak, and F. T. Ozgunen, "An evaluation of risk factors in pregnant women with candida vaginitis and the diagnostic value of simultaneous vaginal and rectal sampling," Mycopathologia, vol. 172, no. 1, pp. 25–36, 2011.
[7] M. Hamad, N. Kazandji, S. Awadallah, and H. Allam, "Prevalence and epidemiological characteristics of vaginal candidiasis in the UAE," Mycoses, vol. 57, no. 3, pp. 184–190, 2014.
[8] T. Meizoso, T. Rivera, M. J. Fernández-Aceñero, M. J. Mestre, M. Garrido, and C. Garaulet, "Intrauterine candidiasis: Report of four cases," Archives of Gynecology and Obstetrics, vol. 278, no. 2, pp. 173–176, 2008.
[9] O. Grigoriou, S. Baka, E. Makrakis, D. Hassiakos, G. Kapparos, and E. Kouskouni, "Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 126, no. 1, pp. 121–125, 2006.
[10] X. Zeng, X. Zhang, T. Zhang, Y. Xue, H. Xu, and R. An, "Risk factors of vulvovaginal candidiasis among women of reproductive age in Xian: a cross-sectional study," BioMed Research International, vol. 2018, Article ID 9703574, 8 pages, 2018.
[11] J.-P. Vermitsky, M. J. Self, S. G. Chadwick et al., "Survey of vaginal flora Candida species isolates from women of different age groups by use of species-specific PCR detection," Journal of Clinical Microbiology, vol. 46, no. 4, pp. 1501–1503, 2008.
[12] R. Wadile and V. Bhate, "Study of clinical spectrum and risk factors of neonatal candidemia," Indian Journal of Pathology and Microbiology, vol. 58, no. 4, pp. 472–474, 2015.
[13] A. Ouanes, A. Kouais, S. Marouen, M. Sahnoun, B. Jemli, and S. Gargouri, "Contribution of the chromogenic medium CHROMagar Candida in mycological diagnosis of yeasts," Journal de Mycologie Médicale, vol. 23, no. 4, pp. 237–241, 2013.
[14] P. Madhavan, F. Jamal, P. P. Chong, and K. P. Ng, "Identification of local clinical Candida isolates using CHROMagar Candida TM as a primary identification method for various Candida species," Tropical Biomedicine, vol. 28, no. 2, pp. 269–274, 2011.
[15] E. Daef, A. Moharram, S. S. Eldin, N. Elsherbiny, and M. Mohammed, "Evaluation of chromogenic media and semi-nested PCR in the identification of Candida species," Brazilian Journal of Microbiology, vol. 45, no. 1, pp. 255–262, 2014.
[16] J. M. Brown, K. L. Hess, S. Brown, C. Murphy, A. L. Waldman, and M. Hezareh, "Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States," Obstetrics & Gynecology, vol. 121, no. 4, pp. 773–780, 2013.
[17] S. Ramia, L. Kobeissi, F. El Kak, S. Shamra, K. Kreidieh, and H. Zurayk, "Reproductive tract infections (RTIs) among married non-pregnant women living in a low-income suburb of Beirut, Lebanon," The Journal of Infection in Developing Countries, vol. 6, no. 09, pp. 680–683, 2012.
[18] I. A. Altabayr, A. S. Alsanoosi, and N. A. Osman, "Prevalence of vaginal candidiasis among pregnant women attending different gynecological clinic at South Libya," European Journal of Experimental Biology, vol. 6, pp. 25–29, 2016.
[19] M. Nelson, W. Wanjiru, and M. W. Margaret, "prevalence of vaginal candidiasis and determination of the occurrence of candida species in pregnant women attending the antenatal clinic of thika district hospital, Kenya," Open Journal of Medical Microbiology, vol. 03, no. 04, pp. 264–272, 2013.
[20] D. C. Nnadi and S. Singh, "The prevalence of genital Candida species isolated from women of different reproductive age groups by use of species-specific PCR detection," Current Infectious Disease Reports, vol. 17, no. 6, article 462, 2015.
[21] M. Hezareh, "Prevalence of clinical and subclinical cervicovaginal infections among pregnant women," American Journal of Obstetrics & Gynecology, vol. 199, no. 1, pp. 121–125, 2006.
[22] M. Lisiak, C. Kłyszejko, T. Pierzchało, and Z. Marcinkowski, "Vaginal candidiasis: frequency of occurrence and risk factors," Ginekologia Polska, vol. 71, no. 9, pp. 964–970, 2000.
[22] D. Nowakowska, A. Kurnatowska, B. Stray-Pedersen, and J. Wilczynski, "Prevalence of fungi in the vagina, rectum and oral cavity in pregnant diabetic women: relation to gestational age and symptoms," Acta Obstetricia et Gynecologica Scandinavica, vol. 83, no. 3, pp. 251–256, 2004.

[23] A. Karaer, M. Boylu, and A. F. Avsar, "Vaginitis in Turkish women: symptoms, epidemiologic—microbiologic association," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 121, no. 2, pp. 211–215, 2005.

[24] S. S. Richter, R. P. Galask, S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller, "Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases," Journal of Clinical Microbiology, vol. 43, no. 5, pp. 2155–2162, 2005.

[25] A. Ahmad and A. U. Khan, "Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 144, no. 1, pp. 68–71, 2009.

[26] D. A. Enoch, H. A. Ludlam, and N. M. Brown, "Invasive fungal infections: a review of epidemiology and management options," Journal of Medical Microbiology, vol. 55, no. 7, pp. 809–818, 2006.

[27] A. A. Akinbiyi, R. Watson, and P. Feyi-Waboso, "Prevalence of Candida albicans and bacterial vaginosis in asymptomatic pregnant women in South Yorkshire, United Kingdom. Outcome of a prospective study," Archives of Gynecology and Obstetrics, vol. 278, no. 5, pp. 463–466, 2008.

[28] G. J. Dennerstein and D. H. Ellis, "Oestrogen, glycogen and vaginal candidiasis," Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 41, pp. 326–328, 2001.

[29] D. D. Glover and B. Larsen, "Relationship of fungal vaginitis therapy to prior antibiotic exposure," Infectious Diseases in Obstetrics and Gynecology, vol. 11, no. 3, pp. 157–160, 2003.

[30] E. Rylander, A.-L. Berglund, C. Krassny, and B. Pettrini, "Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse," Sexually Transmitted Infections, vol. 80, no. 1, pp. 54–57, 2004.

[31] N. Jindal, P. Gill, and A. Aggarwal, "An epidemiological study of vulvovaginal candidiasis in women of childbearing age," Indian Journal of Medical Microbiology, vol. 25, no. 2, pp. 175–176, 2007.

[32] D. Mølgaard-Nielsen, H. Svanstrøm, M. Melbye, A. Hviid, and B. Pasternak, "Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth," Journal of the American Medical Association, vol. 315, no. 1, pp. 58–67, 2016.